Glucagon and GLP-1 receptor co-agonist
Mazdutide 10 mg injection once weekly
MAZD_SC_10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.50 (0.01 to 32.82) | 0.62 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.54 (0.03 to 8.47) | 0.85 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.86 (0.53 to 218) | 0.38 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.07 (0.20 to 7.38) | 0.66 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.48 (0.01 to 40.00) | 0.70 |